PDE4B and idiopathic pulmonary fibrosis: Phase III studies to further characterise the efficacy, safety and tolerability profile of this preferential PDE4B inhibitor in patients with IPF (clinicaltrials.gov NCT05321069) and progressive fibrosing ILD (NCT05321082) started in Q3 2022.